ArticleClinical kidney journal2024
Long-term outcomes of patients with IgA nephropathy in the German CKD cohort.
Article in Clinical kidney journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy: A Systematic Review and Meta-Analysis.Clinical journal of the American Society of Nephrology : CJASN · 2026Pooled it
- Lower proteinuria is better for patients with IgA nephropathy: a systematic review.Frontiers in nephrology · 2025Pooled it
- Immunofluorescence Patterns in IgAN are Associated With Active, Necrotizing Lesions.Kidney international reports · 2026Article
- Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.Clinical kidney journal · 2026Article
- Measuring effectiveness in immunoglobulin A nephropathy: what are we looking for?Clinical kidney journal · 2026Article
- Albuminuria or proteinuria in glomerular disease and CKD-which one to use?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Article
- Treatment practices, characteristics and outcome of immunoglobulin A nephropathy - a Swiss single center experience.Frontiers in nephrology · 2026Article
- Treatment of recurrent IgA nephropathy after kidney transplantation with targeted-release budesonide - a case report.Journal of nephrology · 2025Article
- The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective.Clinical kidney journal · 2025Article
- SGLT2 Inhibitors in Glomerulonephritis: Beyond Nephroprotection?Journal of clinical medicine · 2025Review
- First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.Clinical kidney journal · 2025Article
- Luteolin delays the progression of IgA nephropathy by attenuating inflammation, oxidative stress and reducing extracellular matrix accumulation through activating the Nrf-2/HO-1 pathway.Frontiers in pharmacology · 2025Article
- Prognostic Value of Baseline and Early Proteinuria Changes in IgA Nephropathy: A US Cohort Study.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The importance of albuminuria as opposed to proteinuria in predicting kidney outcomes in primary immunoglobulin A nephropathy (IgAN) is not well established. Methods: From 2010 to 2012, 421 patients with biopsy-proven IgAN have been enrolled into the German Chronic Kidney Disease (GCKD) cohort, a prospective observational cohort study ( Results: The mean age of IgAN patients at baseline was 51.6 years (± 13.6) and 67% were male. The patient-reported duration of disease at baseline was 5.9 ± 8.1 years. Baseline median urine albumin:creatinine ratio (UACR) was 0.4 g/g [interquartile range (IQR) 0.1-0.8] and mean eGFR was 52.5 ± 22.4 ml/min/1.73 m Conclusion: In the GCKD IgAN subcohort, more than every fourth patient experienced a CKE event within 6.5 years. Our findings support the use of albuminuria as a surrogate to assess the risk of poor kidney outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.